.2 deletion syndrome (DS) is the most frequent chromosomal microdeletion syndrome (Botto et al., 2003; Devriendt, Fryns, Mortier, van Thienen, & Keymolen, 1998; Goodship, Cross, LiLing, & Wren, 1998; Oskarsdottir, Vujic, & Fasth, 2004; Tezenas Du Montcel, Mendizabai, Ayme, Levy, & Philip, 1996) . The prevalence of 22q11.2DS has been reported to be 1 in~1,000 unselected fetuses, those without congenital heart disease or cleft palate on prenatal ultrasound, (Grati et al., 2015) and anywhere from 1 per 3,000 to 1 per 6,000 livebirths (Botto et al., 2003; Devriendt et al., 1998; Goodship et al., 1998; Oskarsdottir et al., 2004; Tezenas Du Montcel et al., 1996) . While this condition results in a heterogeneous clinical presentation, it leads to frequent associated features in multiple organ systems, including cardiac anomalies such as interrupted aortic arch type B, truncus arteriosus, tetralogy of Fallot and ventricular septal defects (Goldmuntz et al., 1993; Peyvandi et al., 2013) ; palatal abnormalities (velopharyngeal insufficiency [VPI] , cleft lip, and/or palate); immunodeficiency and autoimmune disease, endocrinopathies (hypoparathyroidism with resultant hypocalcemia, thyroid dysfunction, growth hormone deficiency), genitourinary and gastrointestinal differences, and neurodevelopmental abnormalities (cognitive delays and neuropsychiatric involvement) . Patients also present with atypical features requiring the provider to consider the possibility of a concurrent diagnosis-such as a genetic condition related to/caused by the 22q11.2 microdeletion, or one that is unrelated/ familial/coincidental. As the 22q11.2DS can affect multiple organ systems, it is crucial to consider that a secondary diagnosis may potentiate the symptoms of any single organ system. Less common features reported in patients with 22q11.2DS and overlapping with other well-described conditions include: coloboma, sensorineural and conductive hearing loss, choanal atresia, tracheoesophageal fistula, imperforate anus, IUGR, vertebral anomalies, clubfoot, polydactyly, scoliosis, thrombocytopenia, microcephaly, idiopathic seizures, and hypotonia . These features, while known to be possibly associated with 22q11.2DS, are atypical enough that if they are noted, especially in conjunction with other atypical features, should raise a clinician's suspicion to seek a secondary diagnosis.
Additionally, with the advent of newborn screening, certain highly prevalent genetic disorders are uncovered within a patient's first weeks of life. If one of these patients additionally presents with findings reminiscent of 22q11.2DS, the clinician must still pursue the appropriate testing for this diagnosis. While statistically there is a lower likelihood of carrying two unrelated genetic diagnoses, this series demonstrates instances of these independently common dual diagnoses including cystic fibrosis, glucose 6 phosphate dehydrogenase (G6PD) deficiency, and severe combined immunodeficiency (SCID).
As has been previously reported, a deletion in one 22q11.2 allele can unmask an autosomal recessive disorder should the patient have a deletion/mutation in an important gene on the other allele . It is therefore crucial to give special consideration to these known conditions including a coagulopathy known as Bernard-Soulier syndrome type B due to a mutation in GP1BB (OMIM #231200), CEDNIK syndrome (Cerebral dysgenesis, neuropathy, ichthyosis and keratoderma) due to a mutation in SNAP29 (OMIM #609528), and a condition with severe contractural arachnodactyly and skeletal anomalies known as van den Ende-Gupta syndrome (VDEGS) due to a SCARF2 mutation (OMIM #600920), as well as other genes that may explain atypical features. For example, we have previously reported a patient with 22q11.2DS and BernardSoulier syndrome (Budarf et al., 1995) and four patients with 22q11.2DS and CEDNIK (McDonald-McGinn et al., 2013) . Other groups have reported additional patients with Bernard-Soulier or VDEGS (Bedeschi et al., 2010; Kenny, Morateck, Gill, & Montgomery, 1999; Nakagawa, Okuno, Okamoto, Fujino, & Kato, 2001) . Likewise, patients with 22q11.2DS and a second genetic diagnosis that is not a direct result of the copy number variant causing this deletion syndrome have been previously reported including: one patient from our center with SCID (Heimall et al., 2012) , a patient with a sporadic FGFR3 mutation (Reardon et al., 1997) , and a patient from our cohort with Trisomy 8 mosaicism . Similarly, here we present six unreported patients with coexisting conditions impacting medical management.
| METHODS
Patients with a laboratory confirmed chromosome 22q11.2 deletion via comparative genomic hybridization (CGH), multiplex ligation-dependent probe amplification (MLPA), fluorescent in situ hybridization (FISH), or SNP microarray, and a dual diagnosis were retrospectively identified from our cohort of 1,422 patients (including the seven previously reported cases with coexisting conditions) followed in the 22q and You
Center at the Children's Hospital of Philadelphia (CHOP) under an IRB approved protocol. Of our 1,422 patients, 134 were relatives of the proband (69 mothers, 34 fathers, and 31 siblings), who were affected and presented to medical attention following a proband being diagnosed with 22q11.2 microdeletion syndrome.
| RESULTS
We identified six novel patients with a 22q11.2 deletion and a coexisting condition, resulting in an incidence of dual diagnoses at our center of 0.9%. Clinically available mutational analysis was performed to confirm a suspected diagnosis of cystic fibrosis (CFTR: F508del and c.1329_1330insAGAT, p.Ile444fs*3), and CHARGE syndrome (CHD7: c.3205C > T, p.Arg1069*). Microarray analysis was used to diagnose the 17q12 deletion syndrome and 1q21.1 deletion. Enzyme testing was used to confirm a newborn screen diagnosis of G6PD deficiency and coagulation assays were used to diagnose von Willebrand disease.
Six previously unpublished dual diagnosis patients are summarized in Table 1 , with clinical features by organ system highlighted and attributed to one of the two diagnoses for each patient in Table 2 .
Using previous authors' delineation of distinct vs. overlapping phenotypes (Boycott & Innes, 2017; Posey et al., 2017) , our six patients fall into the following categories: patients 1, 3, and 6 each present with significantly overlapping phenotypes between their dual diagnoses, while patients 2, 4, and 5 demonstrate a mostly distinct secondary phenotype.
3.1 | CHARGE syndrome due to a CHD7 mutation-Patient 1 Patient 1 is a now 26-year-old female with 22q11.2DS and CHARGE syndrome (OMIM #214800) who presented for a routine genetics evaluation soon after birth with a history of esophageal atresia. Perinatal history was complicated by severe polyhydramnios, absence of a stomach bubble, and a heart shifted to the left against the chest wall on fetal ultrasound. An amniocentesis during the pregnancy revealed a normal karyotype (46, XX). The persistent absence of gastric bubble raised the concern for a swallowing abnormality secondary to possible tracheaesophageal fistula. No choanal atresia or heart murmur was noted. A tube could not be passed into the stomach and abdominal X-ray was notable for a lack of gas. Workup as a neonate included X-rays to evaluate for VATER syndrome but vertebrae and other associated features were unremarkable. Ophthalmology exam discovered a unilateral chorioretinal coloboma involving the optic nerve. At 19 years of age the patient re-presented to the genetics department with an additional history of short stature and amenorrhea. At the time of this evaluation, her height, weight, and head circumference were all below the 5th percen- 
| Cystic fibrosis-Patient 2
Patient 2 has both 22q11.2DS and cystic fibrosis (CF) with a history of failure to thrive, sacral dimple, gastroesophageal reflux, pancreatic insufficiency, chronic otitis media, nasal congestion but no evidence of polypoid disease, right perforated tympanic membrane with bilateral myringotomy tubes, velopharyngeal insufficiency, anemia, vitamin D deficiency, and kidney stones. His state newborn screening study raised concerns for a diagnosis of cystic fibrosis (found to have a delta F508 mutation in CFTR); the diagnosis was confirmed with fecal elastase and a sweat chloride test. The patient's mother and father underwent CFTR sequencing. Mother was found to have a delta F508 mutation, and father was heterozygous for a c.1329_1330insAGAT mutation (previously described in association with CF). The insertion is a duplication and creates a stop codon caused by changing the reading frame. A heart murmur was noted on day of life 1 and led to the patient remaining hospitalized for 5 days. A ventricular septal defect (VSD) (with concern for aortic arch hypoplasia) was discovered at 1 week of life requiring repair at 2 months of age. The patient received antibiotics in the newborn period for meconium aspiration concern. Noting the patient's long slender fingers and microcephaly, in conjunction with his VSD, the cardiologist sent testing for 22q11.2DS, which was positive. Parental testing for 22q11.2 deletion via FISH testing was normal.
| 17q12 Deletion syndrome-Patient 3
Patient 3 was evaluated by clinical genetics at 22 months of age for a history of polyhydramnios (and maternal uterus didelphys), failure to thrive, anemia, thrombocytopenia, unilateral multicystic dysplastic kidney, chronic constipation, developmental delay, and short stature. Physical exam revealed a nondysmorphic child at the 3rd percentile for height, 49th percentile for weight, and 40th percentile for head circumference. A sacral dimple and pilonidal cyst were found and a tethered cord was diagnosed by follow-up MRI. Fragile X testing was normal. On genome wide microarray, the child was found to have a 1.49 Mb maternally inherited pathogenic recurrent deletion of 17q12 and a de novo 395 kb nested deletion of chromosome 22q11.2 (LCR22-C to LCR22-D). His 17q12 deletion contains more than 28 RefSeq genes including PIGW, ACACA, and HNF1B. Haploinsufficiency of the HNF1B gene is associated with renal cysts and diabetes syndrome (RCAD) also known as MODY5 with clinical features including nondiabetic renal disease resulting from abnormal renal development, and diabetes. The severity among the patients can be variable (Mefford et al., 2007) .
Additional features associated with the 17q12 deletion syndrome (OMIM #614527) include pancreatic abnormalities, facial dysmorphism, genitourinary differences (including uterus didelphys and cryptorchidism), as well as cognitive and developmental differences (Loirat et al., 2010; Moreno-De-Luca et al., 2010; Palumbo et al., 2014) .
| Glucose 6 phosphate dehydrogenase deficiency-Patient 4
Patient 4 is a 13-year-old African American male with a nested LCR22-B to LCR22-D 22q11.2 deletion, which was detected by Abbreviations (het = heterozygous; MLPA = multiplex ligation-dependent probe amplification). Abbreviations (mo = months old; yo = years old; IEP = individualized education plan; NR = none reported; avg = average; PT = physical therapy; ID = intellectual disability; OT = occupational therapy; ADHD = attention deficit and hyperactivity disorder; italics = overlapping features.
MLPA testing ordered by his pediatrician; the test was performed due to a history of autism spectrum disorder, hypernasal speech (possible VPI), a high T4 count, overfolded auricles, intermittent episodes of vomiting, asthma, headaches, bilateral pes planus, and a learning disability. Fragile X testing was also performed and was normal. The patient is mildly dysmorphic with slightly overfolded helices, bilateral crumpled ears, long narrow nose with narrow nasal bridge and nasal tip, a high arched palate, malar flattening, and hyperpigmentation on his phallus. Glucose-6-phosphate dehydrogenase deficiency is included in the newborn screen in some states and was confirmed in this child at 9 months of age, when his Glucose-6-phosphate dehydrogenase studies revealed a low level-1.3 U/g Hb (normal range:
4.6-13.5 U/g Hb), with normal hematocrit, hemoglobin, and mean corpuscular volume. The G6PD level was verified by repeat analysis according to the lab report. He has never had a blood transfusion.
| Von Willebrand disease-Patient 5
Patient 5 was diagnosed with 22q11.2DS at 5 years 9 months of age when his cardiologist noted, in addition to his previously diagnosed VSD and interrupted aortic arch, that the child was experiencing speech difficulties due to palatal insufficiency. He too was found to have a nested LCR22A-LCR22B 22q11. 
| DISCUSSION
With the advent of whole exome sequencing (WES), the phenomenon of multiple genetic diagnoses in a single patient is becoming more widely recognized (Boycott & Innes, 2017) . Recent studies have found a multiple genetic diagnosis rate in patients found to have at least one molecular diagnosis on WES of 4.9% (Posey et al., 2017) , 3.2% (Retterer et al., 2016) , and 6.5% (Yang et al., 2013) . Of the 2,076 patients in Posey et al.'s article who were found to have at least one molecular diagnosis, 12 patients (0.6%) were found to have a causal copy-number variant as one of their multiple diagnoses (Posey et al., 2017) . Similarly, from our cohort of 1,422 patients who each harbor at least one causal copy-number variant, specifically the 22q11.2 microdeletion, 0.9% of these patients were found to have a second genetic diagnosis. We have reason to believe that this 0.9% dual diagnosis rate is an underestimation, since clinicians may stop searching for a cause after confirming an early diagnosis of 22q11.2DS and may not consider alternate explanations for an atypical phenotype, especially due to this microdeletion's known heterogeneous pathogenicity. Conversely, patients referred for WES will inevitably have all of their genetic diagnoses uncovered simultaneously, preventing the bias of prematurely ending a diagnostic odyssey when one reasonable explanation is found.
This case series highlights the clinical importance of attending closely to patients who present with features that are inconsistent with a diagnosis of 22q11.2 deletion or exceed the severity generally associated with this diagnosis. Previous reports of clinicians investigating for a secondary diagnosis often occur when a disease with a well-known phenotype presents with atypical severity (Jehee et al., 2017) . For example, while the individual features of esophageal atresia, optic nerve coloboma, and sensorineural hearing loss, can each be observed in 22q11.2DS, the combination of all three in a single patient triggered consideration of an alternative unifying diagnosis, in this case CHARGE syndrome.
| Previous reports of 22q11.2DS and a second diagnosis
Previously published cases of 22q11.2DS with unrelated concomitant secondary genetic disorders include trisomy 8 mosaicism, Artemis deficiency (a rare form of severe combined immunodeficiency), and a sporadic case of FGFR3 mutation (Table 3) . Autosomal recessive disorders unmasked by a 22q11.2 microdeletion, which have also been previously reported, include CEDNIK, Bernard-Soulier syndrome, and van den Ende-Gupta syndrome (Table 3 ) (Budarf et al., 1995; McDonaldMcGinn et al., 2013) . The 22q11.2DS diagnosis was made in the setting of specific testing conducted to explain the patient's truncus arteriosus and polydactyly.
For the previously reported cases in the literature, Bernard-Soulier syndrome was often the initial or simultaneous diagnosis made (Kenny et al., 1999; Nakagawa et al., 2001 ). The VDEGS diagnosis was made secondarily upon sequencing SCARF2 in a patient who phenotypically presented with VDEGS and was initially found to have a heterozygous deletion of 22q11.2 (Bedeschi et al., 2010) . The FGFR3 mutation was uncovered after the 22q11.2 deletion, as an explanation for the patient's craniosynostosis and broad thumbs (Reardon et al., 1997) .
| Clues to pursuing a second diagnosis
It is worth noting that most of the six newly reported dual diagnosis cases presented in this series harbor nested deletions. This may have been the impetus in certain cases to search for an alternative diagnosis, when the severity seemed out of proportion especially for a patient harboring a nested deletion. In regards to patient 1, the gene Family history can help direct diagnosis as well. The proband in case 3 has an extensive family history of renal disease, some of it fatal in the newborn period. Mother of proband, who is also affected with 17q12 deletion, has a learning disability (she completed high school), and uterus didelphys (two uteri and two cervices). The proband had a maternal half-brother who died at several hours of life due to multicystic kidneys and an unspecified spinal cord/neural tube defect. The patient had two maternal aunts, one with a cardiac anomaly and another with kidney problems. The maternal grandfather had kidney issues, two great aunts had uterus and cervix anomalies, and a maternal great uncle died after birth with kidney disease.
| Implications to clinical management
Accurate diagnostics allows for more personalized and appropriate medical management. The gastrointestinal complications that can be seen in 22q11.2DS include esophagitis, aspiration, choking and recurrent pneumonia, failure to thrive, malnutrition, and feeding refusal (Dyce et al., 2002; Eicher et al., 2000) . Older children and adults often experience recurrent and chronic sinus infections as a sign of nasopharyngeal reflux as this results in repeated contamination of the nasal cavity Dyce et al., 2002; McDonald-McGinn et al., 1997; McDonald-McGinn et al., 1999; McDonald-McGinn et al., 2001; Ruotolo et al., 2006; Solot et al., 2001; Stransky et al., 2015; Widdershoven et al., 2013) . Patients with cystic fibrosis often first present with Bernard-Soulier syndrome Unmasked AR Budarf et al., 1995; Kenny et al., 1999; Nakagawa et al., 2001 Van Abbreviations (AR = autosomal recessive).
conditions. Early and aggressive management of symptoms can impact long-term outcome and quality of life.
The recommendations for vaccines and prophylactic treatment must be carefully examined in patients with 22q11.2DS and cystic fibrosis. 22q11.2DS patients with very low T cell counts should not be administered live viral vaccines. Patients with no CD45RA T cells should receive prophylaxis against pneumocystis (Butcher et al., 2012; Hamilton, Husein, & Dworschak-Stokan, 2008; Hofstetter et al., 2014; Moylett, Wasan, Noroski, & Shearer, 2004; Perez, Bokszczanin, McDonald-McGinn, Zackai, & Sullivan, 2003) . According to 2016
Clinical Practice Guidelines From the Cystic Fibrosis Foundation for Preschoolers With Cystic Fibrosis (Lahiri et al., 2016) , children should receive age-appropriate immunizations and annual seasonal influenza vaccination along with family members and caregivers. Furthermore, it is recommended that 22q11.2DS patients with autoimmune diseases should be managed with minimal immunosuppression treatment if possible (Maggadottir & Sullivan, 2013) . Patients with CF may require a lung transplant at a certain stage of their life and disease, which would be accompanied by subsequent necessary immunosuppression.
These are the types of medical decisions that need to be carefully weighed and considered in treating patients with dual diagnoses.
With a diagnosis of CF comes a risk of cystic fibrosis related diabetes (CFRD). Diabetes and adult-onset obesity has been studied in 22q11.2DS. The age of onset for type 2 diabetes was noted to be similar to the age of onset in adults with Prader-Willi syndrome; the median age of diagnosis for type 2 diabetes in 22q11.2DS (10 patients in a cohort of 207) was 39.5 years compared to all types of diabetes for adults in the general U.S. population which is 54.2 years (Sinnema et al., 2011; Voll et al., 2017) . Voll et al.'s study suggests that psychotic illness (and therefore psychotropic medications) may be a contributing factor to the obesity observed in adults with 22q11.2DS, but not the sole cause. It is important that clinicians are aware of this risk when considering prescription of psychotropic medication, especially if coupled with an even greater risk for diabetes due to a secondary diagnosis. Similar to patient 2, with a dual diagnosis of CF and 22q11.2DS, the risk of diabetes in patient 3 also comes from two separate diagnoses. The gene included in patient 3's 17q12 deletion, which is associated with renal anomalies and increased risk of diabetes, is HNF1B (Palumbo et al., 2014) .
Patient 5 demonstrates that despite a phenotypic feature being consistent with an underlying diagnosis, it is important to investigate further when a symptom seems more severe than expected for one particular diagnosis. 22q11.2DS is sometimes associated with platelet abnormalities, such as Bernard-Soulier syndrome or storage pool deficiency. These patients will have bleeding symptoms. Many more patients with the deletion have mildly low platelet counts with elevated mean platelet volume (Lambert et al., 2017 (Costain, Chow, Silversides, & Bassett, 2011) ; this coupled with the infertility seen in patients with cystic fibrosis is an important counseling concern when discussing reproductive health with patients.
| CONCLUSION
It is imperative that clinicians diagnose and remain cognizant of the phenotypic overlap within the dual diagnoses of their patients. Overlapping features often make a secondary diagnosis more difficult to discover, or lead to a delay in secondary diagnosis, since medical teams often conclude a diagnostic odyssey when a fitting explanation for a symptom is found. The phenotypic overlap between 22q11.2DS
and CHARGE syndrome may both make the diagnosis more difficult and may also lead to more severe organ involvement. Premature mortality occurs in 22q11.2DS, and early deaths in the infant age group are in part due to cardiac defects, hypocalcemia, and airway malacia Repetto et al., 2014) .
The fact that overall mortality for those with 22q11.2DS is greater than the mortality rates observed in nonsyndromic individuals with similar cardiac defects (Repetto et al., 2014) is one piece of evidence pointing to the fact that syndromes themselves can affect overall morbidity and mortality; it is not merely the exact sum of the parts of symptomatic organ involvement that can contribute to overall prognosis. It is unclear how two concurrent genetic syndromes in a single patient may impact that patient's overall clinical course. As cytogenetic and molecular diagnoses become more widespread, and there are more instances of dual diagnoses uncovered, we may be able to provide better prognostic evidence for this cohort of patients.
From a practical standpoint, it is important that one diagnosis not over-shadow the needs of the other; the impact that treatment of one condition may have on the other must be considered. In light of our findings, it is not necessarily prudent or costeffective to consider whole exome sequencing in all of these patients but is instead wise to consider multiplex clinical tests on all 22q11.2DS patients, instead of only an MLPA. This can be accomplished by assessing for a CNV at 22q11.2 and a mutation in a presumed involved or important gene on the nondeleted allele, along with conducting a full microarray. Furthermore, WES can then be reserved for patients with atypical findings, which will prove a prudent economic decision based on current cost and resource utilization.
With the high utilization of hospital visits (inpatient and outpatient) of patients with 22q11.2DS, it is especially important to investigate and document all secondary diagnoses, in order to provide the safest and highest quality care to this population.
New cases of dual diagnoses within the 22q and You Center's cohort are continually surfacing as our clinical knowledge regarding unmasked recessive diseases on the non-deleted allele and the clinical presentations associated with these genes becomes more well defined. Investigations into these mutations on the nondeleted allele are currently underway as part of our international 22q11.2 Brain and Behavior Consortium.
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